Antibiotics after incision and drainage for uncomplicated skin abscesses: a clinical practice guideline

Mieke Vermandere,1 Bert Aertgeerts,1,2 Thomas Agoritsas,3 4 Catherine Liu,5 Jako Burgers,6 7 Arnaud Merglen,8 Patrick Mbah Okwen,9 Lyubov Lytvy,3 10 Shunjie Chua,11 Per O Vandvik,12 13 Gordon H Guyatt,3 Claudia Beltran-Arroyave,14 Valéry Lavergne,15 Reinhart Speeckaert,16 Finn E Steen,17 Victoria Arteaga,18 Rachelle Sender,19 Shelley McLeod,20 Xin Sun,21 Wen Wang,21 Reed A C Siemieniuk3 22

What role do antibiotics have in the treatment of uncomplicated skin abscesses after incision and drainage? A recent study suggested that, for small uncomplicated skin abscesses, antibiotics after incision and drainage improve the chance of short-term cure compared with placebo. Triggered by this trial, the Rapid Recommendation team produced a new systematic review. Relying on this review and using the GRADE framework according to the BMJ Rapid Recommendation process, an expert panel makes a weak recommendation in favour of trimethoprim-sulfamethoxazole (TMP-SMX, co-trimoxazole) or clindamycin in addition to incision and drainage over incision and drainage alone. For patients who have chosen to initiate antibiotics, the panel issues a strong recommendation for TMP-SMX or clindamycin rather than a cephalosporin and a weak recommendation for TMP-SMX rather than clindamycin. The box overleaf shows the articles and evidence linked to this Rapid Recommendation. The infographic presents the recommendations together with other pertinent information, including an overview of the absolute benefits and harms of candidate antibiotics in the standard GRADE format. The panel emphasises shared decision making in the choice of whether to initiate antibiotics and in which antibiotic to use, because the desirable and undesirable consequences are closely balanced: clinicians using MAGICapp (http://magicapp.org/goto/guideline/jJRvQn/section/ER5RAn) will find decision aids to support the discussion with patients. Table 2 below shows any evidence that has emerged since the publication of this article.

WHAT YOU NEED TO KNOW

- For bacterial skin infections, we suggest using trimethoprim-sulfamethoxazole (TMP-SMX) or clindamycin in addition to incision and drainage rather than incision and drainage alone, but we emphasise the need for shared decision making because the modest benefits of TMP-SMX or clindamycin will be outweighed by the side effects and burdens for many patients.
- TMP-SMX or clindamycin modestly reduces pain and treatment failure and probably reduces abscess recurrence, but increase the risk of adverse effects including nausea and diarrhoea.
- We suggest TMP-SMX rather than clindamycin because TMP-SMX has a lower risk of diarrhoea.
- Cephalosporins in addition to incision and drainage are probably not more effective than incision and drainage alone in preventing treatment failure in most settings.
- We take an individual patient perspective in creating our recommendations. From a societal perspective, the modest benefits from adjuvant antibiotics may not outweigh the risk of antimicrobial resistance in the community.

No commercial reuse: See rights and reprints http://www.bmj.com/permissions
Rapid Recommendations

**Population**

This recommendation applies to almost all patients with skin abscesses:
- Unknown or unconfirmed pathogen(s)
- Emergency and primary care settings

However, the recommendation is **not** applicable to patients with:
- Evidence of systemic illness (sepsis)
- Pustules and papules
- Deep tissue infections
- Hidradenitis suppurativa
- Immunocompromising conditions
- Patients who do not undergo incision and drainage

**Comparison 1**

<table>
<thead>
<tr>
<th>No antibiotics</th>
<th>Antibiotics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incision and drainage alone</td>
<td>Incision and drainage plus trimethoprim and sulfamethoxazole or clindamycin</td>
</tr>
</tbody>
</table>

** Applies to:** All

We suggest TMP-SMX or clindamycin plus incision and drainage rather than incision and drainage alone. Discuss both options with each patient.

**Comparison 2**

For patients who have chosen to initiate antibiotics:

<table>
<thead>
<tr>
<th>Trimethoprim and sulfamethoxazole or Clindamycin</th>
<th>Cephalosporins</th>
</tr>
</thead>
<tbody>
<tr>
<td>First and second generation cephalosporins</td>
<td></td>
</tr>
</tbody>
</table>

** Applies to:** Those initiating antibiotics

We recommend trimethoprim and sulfamethoxazole or clindamycin over cephalosporins.

**Comparison 3**

For patients who have chosen to initiate antibiotics:

<table>
<thead>
<tr>
<th>Clindamycin</th>
<th>Trimethoprim and sulfamethoxazole</th>
</tr>
</thead>
</table>

** Applies to:** Those initiating antibiotics

We suggest trimethoprim and sulfamethoxazole over clindamycin. Discuss with patients in shared decision making.
common pathogens are *Staphylococcus aureus*, most often methicillin-resistant (MRSA), and several other bacteria, most originating from the skin flora. MRSA accounts for a substantial number of visits by patients with skin and soft tissue infections. The Rapid Recommendations team believed these two trials, in addition to the existing body of evidence, might change practice. As with all BMJ Rapid Recommendations, no panel member had financial conflicts of interest; intellectual and professional conflicts were minimised and managed (see appendix 1 on bmj.com).

The panel followed the BMJ Rapid Recommendations procedures for creating a trustworthy recommendation, including using the GRADE approach to critically appraise the evidence and to move from evidence to recommendations (appendix 2 on bmj.com). The panel initially identified patient-important outcomes and subgroup hypotheses needed to inform the recommendation. When creating the recommendation, the panel considered the balance of benefits, harms, costs, burdens of the treatments, the quality of evidence for each outcome, typical patient values and preferences and their expected variations, as well as acceptability.

Recommendations can be strong or weak, for or against a course of action. The recommendations take a patient-centred perspective which de-emphasises public health, societal, and health payer point of view. Explicit descriptions of abscess definitions, for each trial, were summarised in the accompanying systematic review (table C of appendix 2). The largest trial specifically focused on small abscesses (all <5 cm diameter and about half ≤2 cm) in patients who had no signs of systemic infection. The RCTs included participants with skin abscesses anywhere on the body.

Eleven trials reported study setting, of which nine were conducted in emergency departments, one in outpatient dermatology clinics, and one in an Integrated Soft Tissue Infection Services (ISIS) clinic involving patients with high rates of comorbidity, such as infection with hepatitis C, hepatitis B, or HIV. The RCTs included children and adults. Almost all patients underwent incision and drainage for their skin abscess. The most common pathogen was MRSA (49-88%) followed by meticillin-sensitive *Staphylococcus aureus* (MSSA, 9-18%).

### Understanding the recommendation

#### Absolute benefits and harms

The infographic provides an overview of the recommendations and the absolute benefits and harms of different antibiotics. Estimates of the baseline risk for side effects are derived from the control groups of the trials in the systematic review. Detailed information can also be viewed through MAGICapp, including consultation decision aids designed to support shared decision making with patients.

This clinical practice guideline is applicable to patients with uncomplicated skin abscesses, which means that it is not applicable to patients with evidence of systemic
illness (such as sepsis), deep tissue infections, superficial infections (such as pustules and papules), hidradenitis suppurativa, or immunocompromising conditions, and patients who do not undergo incision and drainage.

The first recommendation relates to the usefulness of adjuvant TMP-SMX or clindamycin compared with no antibiotics in addition to incision and drainage. The effects of other antibiotics are speculative, except for cephalosporins, which are probably less effective or not effective (see evidence summary for recommendation No 2). Compared with no antibiotics, TMP-SMX or clindamycin reduces the absolute risk of treatment failure by approximately 5% at one month (high quality evidence). In patients who were cured, these antibiotics reduced the absolute risk of recurrence at three months by approximately 8% (high quality evidence). When considering both treatment failure and abscess recurrence, antibiotic therapy thus provides an approximate 13% reduction (high quality evidence). TMP-SMX or clindamycin probably provide a modest reduction in pain (tenderness) during treatment (7% fewer), and a small reduction in hospitalisation (2% fewer) and in similar infections among household contacts (2% fewer) (all moderate quality evidence). Considering the characteristics of involved patients and medical conditions may differ between emergency departments and general practice.

Fig 1 | Characteristics of patients and trials included in systematic review of the effects of antibiotics on uncomplicated skin abscesses. (MRSA = meticillin resistant Staphylococcus aureus; MSSA = meticillin susceptible S. aureus)
practices, antibiotics may confer an even smaller benefit in patients who present to their GP. Antibiotics probably do not reduce the risk of serious or invasive infections or death (moderate quality evidence).

The occurrence of adverse effects depends on the antibiotic. With clindamycin, the risk of gastrointestinal side effects (predominately diarrhoea) is approximately 10% higher than with no antibiotics (high quality evidence). TMP-SMX probably increases the risk of gastrointestinal side effects by a smaller amount (approximately 2%; moderate quality evidence), and it is predominately nausea rather than diarrhoea. The severity of antibiotic-associated diarrhoea was not described, but is likely to range from mild to severe. Two large trials monitored for Clostridium difficile infection with routine clinical monitoring and no such infection occurred in any treatment arm.15

Overall, there is no important difference in treatment failure between TMP-SMX and clindamycin (high quality evidence). In patients who were initially cured, one study suggested that clindamycin may reduce the risk of early recurrence at one month by approximately 7% (low quality evidence),5 but the confidence interval was wide and this result is inconsistent with indirect evidence from other RCTs, which suggests that the reduction in risk of abscess recurrence compared with placebo is similar for both TMP-SMX and clindamycin. Whether clindamycin reduces abscess recurrence more than TMP-SMX is therefore uncertain (low quality evidence). Local resistance patterns may affect the relative effectiveness of each antibiotic option.7-10 Clindamycin has a 10% higher risk of antibiotic-associated diarrhoea than TMP-SMX (high quality evidence).

The panel also considered evidence for cephalosporins compared with TMP-SMX and clindamycin used for uncomplicated skin abscesses. The network meta-analysis suggested that, at least in settings with a substantial prevalence of MRSA, cephalosporins in addition to incision and drainage probably do not reduce treatment failure compared with incision and drainage alone (moderate quality evidence). Both early and later generation cephalosporins probably confer a higher risk of treatment failure compared with either TMP-SMX or clindamycin (moderate quality evidence). The RCTs investigating cephalosporins did not report sufficient information to directly compare other outcomes. However, the panel felt that cephalosporins were unlikely to provide any other benefits if they do not reduce the risk of treatment failure compared with placebo (low quality evidence). This evidence directly applies to almost all settings where the prevalence of MRSA is more than 10%.12

The panel is confident that the evidence applies to almost all patients with uncomplicated skin abscesses treated with incision and drainage: adults and children, patients presenting to emergency departments and to primary care practices, smaller and larger abscesses, first abscess occurrences and recurrences, and abscesses with unknown infection pathogens. The systematic review and meta-analyses contained adequate representation from such groups and settings, and results were consistent between pre-specified subgroups.15

Values and preferences
The panel believes that there is a high degree of variability between patients and carers weighing the expected desirable and undesirable consequences of antibiotic therapy compared with no antibiotic therapy. This variation is reflected in the weak recommendation, which warrants shared decision making to ensure that each individual’s decision is in line with what they consider most important. The expected benefit of antibiotic therapy in reducing pain, risk of treatment failure, and recurrence is modest, but large enough that the panel anticipates that most fully informed patients would value these benefits sufficiently to choose antibiotic treatment. This might particularly be the case when, for example, the abscess is very painful, perhaps because of location in sensitive places (such as groin, axillae, etc).

For patients who decide to initiate antibiotic treatment, reasonable choices include either TMP-SMX or clindamycin. In some settings, cephalosporins or other antibiotics are often prescribed for skin abscesses. Given that, in most circumstances, cephalosporins probably do not provide any additional benefit beyond incision and drainage alone, the panel felt that all or almost all patients would choose to use antibiotic options with proven efficacy (TMP-SMX or clindamycin), hence the strong recommendation against cephalosporins.

People who place a higher value on the possibility of avoiding abscess recurrence may choose clindamycin, while those who place a higher value on avoiding diarrhoea and on minimising costs are likely to prefer TMP-SMX.

Person-centred versus societal perspective (impact on antibiotic resistance)

The recommendations explicitly take a person-centred perspective rather than a public health or societal perspective. The use of antibiotics is associated with the emergence of antibiotic resistance within the community and may increase the risk of antibiotic resistant infections in community members. The increasing rates of antimicrobial resistance are a public health priority. From a societal perspective, it is possible that the modest benefits from adjuvant antibiotics in this scenario would not outweigh the risk of increased antimicrobial resistance in the community. However, the impact of an individual course of antibiotics on community resistance rates is unknown. Therefore, whether antibiotics in this situation provide a net benefit or harm to society is highly speculative. Clinicians engaging in shared decision making can also address the issue of antibiotic resistance or the local prevalence of other pathogens (such as Panton-Valentine leukocidin (PVL) positive Staphylococcus aureus) with patients facing this decision.

Practical issues and other considerations
Figure 2 outlines the key practical issues for patients and clinicians discussing initiating antibiotics for uncomplicated skin abscesses after incision and drainage, which are also accessible as decision aids along with the evidence in an expanded format to support shared decision making in MAGICapp. The antibiotic course was typically...
## RAPID RECOMMENDATIONS

<table>
<thead>
<tr>
<th>Trimethoprim and sulfamethoxazole</th>
<th>Clindamycin</th>
<th>No antibiotics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MEDICATION ROUTINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>One or two pills twice a day</td>
<td>One pill three to four times per day</td>
<td>May require concomitant over the counter pain relievers</td>
</tr>
<tr>
<td>May require concomitant over the counter pain relievers</td>
<td>May require concomitant over the counter pain relievers</td>
<td></td>
</tr>
<tr>
<td><strong>TESTS &amp; VISITS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>May need additional visits if symptoms do not resolve or worsen</td>
<td></td>
</tr>
<tr>
<td><strong>ADVERSE EFFECTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mid adverse effects (e.g. diarrhoea, nausea) are possible</td>
<td>Substantial risk of antibiotic-associated diarrhoea, which can sometimes be severe</td>
<td>Increased risk of antibiotic resistance in the community</td>
</tr>
<tr>
<td>In rare cases, can cause drug rash with eosinophilia and systemic symptoms (DRESS) or toxic epidermal necrolysis. Although extremely rare, these side effects can be life-threatening</td>
<td>In rare cases, can cause DRESS or toxic epidermal necrolysis. Although extremely rare, these side effects can be life-threatening</td>
<td>Increased risk of antibiotic resistance in the community</td>
</tr>
<tr>
<td>Increased risk of antibiotic resistance in the community</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EMOTIONAL WELL-BEING</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression and hallucinations are reported very rarely</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td><strong>PREGNANCY &amp; NURSING</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDA class D: TMP-SMX may increase the risk of congenital malformations such as neural tube defects. It should be avoided in pregnancy, especially in the first trimester, unless possible</td>
<td>FDA class B: Clindamycin crosses the placenta, but has not been shown to cause harm in pregnancy. No dose adjustment required in pregnancy</td>
<td></td>
</tr>
<tr>
<td><strong>COSTS &amp; ACCESS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inexpensive</td>
<td>May be expensive in some settings</td>
<td></td>
</tr>
<tr>
<td>Available by prescription in most resource-rich countries</td>
<td>Available over the counter in many countries</td>
<td></td>
</tr>
<tr>
<td><strong>FOOD &amp; DRINK</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Often decreases appetite. Should be taken after a meal</td>
<td>Often decreases appetite. Should be taken with a glass of water to avoid oesophageal irritation</td>
<td></td>
</tr>
</tbody>
</table>

---

Fig 2] Practical issues about use of antibiotics after incision and drainage of uncomplicated skin abscesses. (FDA = US Food and Drug Administration)

---

five to 10 days in the RCTs, and dosing varied. TMP-SMX may slightly increase the risk of congenital malformations, including neural tube defects, when prescribed to pregnant women.

### Costs and resources

TMP-SMX is inexpensive; clindamycin is probably more expensive in most places. However, the overall impact on costs to the individual and the healthcare payer are uncertain when the consequences of each option are considered.

### Future research

Key research questions to inform decision makers and future guidelines are:
- What is the impact of different types of antibiotics in settings where MRSA is rare (prevalence <10%)?
- Do antibiotics have different effects in different populations, such as people who are immunocompromised or in people with recurrent skin abscesses?
- What are the long term effects (such as >6 months) of antibiotics on abscess recurrence, *Clostridium difficile* infection, and MRSA resistance to TMP-SMX or clindamycin?
- Is a shorter course of antibiotics (such as 5 days) as effective as a longer course (10 days)?
- Is topical therapy (such as iodine, honey, silver, other antimicrobials) effective for treating uncomplicated skin abscesses compared with systemic therapy? Do other adjunctive measures, such as nasal decontamination or antisepsis for the body, reduce the risk that skin abscesses will recur?
Table 2 shows evidence which has emerged since the publication of this article. As new evidence is published, a group will assess the new evidence and make a judgment on to what extent it is expected to alter the recommendation.

Competing interests: All authors have completed the BMJ Rapid Recommendations disclosure form and a detailed, contextualised description of all disclosures is reported in appendix 2 on bmj.com. As with all BMJ Rapid Recommendations, the executive team and The BMJ judged that no panel member had any financial conflict of interest. Professional and academic interests are minimised as much as possible, while maintaining necessary expertise on the panel to make fully informed decisions.

Funding: This guideline was not funded. R Sériemniuk is partially funded through a Varían Canada Graduate Scholarship.

Transparency: B Aringeet's affirms that the manuscript is an honest, accurate, and transparent account of the recommendation being reported, that no important aspects of the recommendation have been omitted, and that any discrepancies from the recommendation as planned (and, if relevant, registered) have been explained.

Updates to this article


Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/